Research Article: Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis
Introduction:
Bimekizumab is a monoclonal IgG antibody that selectively inhibits the pro inflammatory cytokine interleukin (IL)-F, in addition to IL-A, which are key independent drivers of chronic inflammation. , The safety and efficacy of bimekizumab treatment has been evaluated in Phase and trials of patients with active psoriatic arthritis (PsA), psoriasis and axial spondyloarthritis, with clinically meaningful improvements observed across all patient populations. – The drug is administered subcutaneously, either by a…
Read more